Latest In Research

The good news is that treatment options for lung cancer patients are rapidly improving. In the last two years, more treatments have been approved by the United States Food and Drug Administration (FDA) for the treatment of lung cancer than had been approved in the prior ten years. New and life saving treatments, along with clinical trials, are happening rapidly and LCFA is committed to keeping you up to date on the latest, most hopeful and helpful, information.

06/7
2017

ASCO 2017: Alectinib halts lung cancer growth more than a year longer than crizotinib

Findings from a phase III clinical trial point to a more effective initial treatment for patients with ALK-positive non-small cell lung cancer (NSCLC). Learn more More Lung Cancer Research News:…

05/22
2017

Lab on a Chip Outlines New Liquid Biopsy Technology

Lab on a Chip publication outlines a new technology that may be an important tool for liquid biopsies. Read the UCLA Patient Newsletter Read the abstract…

05/18
2017

A newly released study shows that Durvalumab (Imfinzi) significantly improved progression-free survival when used as a sequential treatment in patients with locally-advanced, unresectable non–small cell lung cancer (NSCLC) who had not pro…

05/12
2017

FDA Approves Keytruda Combo for Lung Cancer

The Food and Drug Administration (FDA) has granted an accelerated approval to Keytruda (pembrolizumab) for use in combination with chemotherapy as a frontline treatment for patients with metastatic or advanced nonsquamous non–small cell l…

05/4
2017

Brigatinib

On April 28, 2017, the U.S. Food and Drug Administration granted accelerated approval to brigatinib for the treatment of patients with metastatic anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) who have progress…

05/1
2017

FDA Grants Lorlatinib Breakthrough Designation for NSCLC

[caption id="attachment_1562" align="aligncenter" width="850"] Senior woman with lung cancer during medical visit[/caption] FDA Grants Lorlatinib Breakthrough Designation for NSCLC: “This regulatory designation recognizes the potential for…

04/28
2017

DNA-based test can spot cancer recurrence a year before conventional scans

A revolutionary blood test has been shown to diagnose the recurrence of cancer up to a year in advance of conventional scans in a major lung cancer trial. Read more…

04/18
2017

Pre-surgical Immunotherapy Trial to Open at UCLA Main Campus

Pre-surgical Immunotherapy Trial UCLA Main Campus: Stage IB, II, IIIA non-small cell lung cancer Exciting announcement from Thoracic Oncology Translational Research at UCLA: Upcoming opening of a pre-surgical immunotherapy trial for…

04/18
2017

AACR Annual Meeting 2017: Panel Discusses the Affordable Care Act

Can we make the ACA better? The legislation was the focus of a panel held at the American Association for Cancer Research Annual Meeting 2017. Read more: http://blog.aacr.org/aacr-annual-meeting-2017-panel-discusses-affordable-care-a…

04/18
2017

AACR Annual Meeting 2017: Immunotherapy Provides Long-lasting Responses to Certain Cancer Types

  Are responses to immunotherapy for lung cancer durable? According to data presented at AACR's 2017 Annual Meeting, from a number of clinical trials, the answer appears to be “Yes.” For many patients whose cancers responded …

Progredientibus autem aetatibus sensim tardeve potius quasi